GUSPERIMUS TRIHYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H37N7O3.3ClH
Molecular Weight	496.904
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of GUSPERIMUS TRIHYDROCHLORIDE

SMILES

Cl.Cl.Cl.NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N

InChI

InChIKey=AXSPHUWXYSZPBG-UHFFFAOYSA-N

InChI=1S/C17H37N7O3.3ClH/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20;;;/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23);3*1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 3 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H37N7O3
Molecular Weight	387.5208
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Gusperimus is an antibiotic, isolated from cultures of the soil commensal Bacillus laterosporus. It possess immunosuppressive properties and exerts its effect through binding to heat shock proteins Hsp90 and Hsc70. Although initially, the drug was being investigated for the treatment of cancer, it recieved orphan designation for the treatment of refractory Wegener’s granulomatosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Heat shock protein HSP90 35	Binding Agent 1,076
Heat shock 70 kDa protein 1A 4	Binding Agent 1,076
Heat shock 70 kDa protein 1B 3	Binding Agent 1,076

Conditions

Condition	Modality	Targets	Highest Phase	Product
Wegener’s granulomatosis 5	Primary		Approved 8,583	SPANIDIN

PubMed

Show entries

Title	Date	PubMed
Significant effect of HLA-DRB1 matching on acute rejection of kidney transplants within 3 months.	2001 Feb-Mar	11267248
Pretreatment of HL60 cells with Deoxyspergualin enhances trail-induced apoptosis independent of caspase 3 activation.	2001 Feb-Mar	11266818
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.	2002	12102646
15-Deoxyspergualin protects the islet graft from macrophage-mediated injury.	2002 Aug	12176438
15-Deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis.	2002 Aug 2	12021268

Showing 1 to 5 of 22 entries

Previous1 2 3 4 5Next

Patents

Sample Use Guides

In Vivo Use Guide

0.5 mg/kg body weight (BW)

Route of Administration: Intravascular

In Vitro Use Guide

To test whether Gusperimus influences the proloferative response of human B-cells, the cells were cultured on CDw32L with 1 ug/ml anti-CD40 mAb with or without IL-10 (100 ng/ml), IL-2 (500 U/ml) or IL-4 (500 U/ml) for 7 days. The drug was added at concentration of 0.2-200 ug/ml. The drug inhibited the prolifirative response of anti-CD40 stimulated B lymphocytes. The inhibition varied among cultures from 48% to 85% at 200 ug/ml.